tinzaparin sodium - Profile

What are the generic sources for tinzaparin sodium and what is the scope of freedom to operate?

Tinzaparin sodium is the generic ingredient in one branded drug marketed by Leo Pharma As and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for tinzaparin sodium

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for tinzaparin sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Leo Pharma As	INNOHEP	tinzaparin sodium	INJECTABLE;INJECTION	020484-001	Jul 14, 2000		DISCN	No	No

Investment Scenario and Fundamentals Analysis for Tinzaparin Sodium

Last updated: February 23, 2026

What is Tinzaparin Sodium?

Tinzaparin sodium is an anticoagulant classified as a low molecular weight heparin (LMWH). It inhibits factor Xa and IIa, reducing clot formation. Approved primarily for deep vein thrombosis (DVT) treatment and prophylaxis, it enters a mature market with competition from agents like enoxaparin and dalteparin.

Market Overview

Parameter	Data	Source
Global LMWH market size	$14.3 billion (2022)	MarketResearch.com [1]
CAGR (2023–2028)	6.2% per annum	MarketsandMarkets [2]
Major players	Sanofi, Bayer, Takeda, Hikma	Company reports [3]
Common indications	DVT, PE, unstable angina	FDA Melux Data [4]

Market Dynamics

Tinzaparin sodium faces a patent expiration landscape, with several competing LMWHs already off-patent. The drug’s market is primarily driven by hospital use, with emerging markets showing demand growth. Competition’s pricing pressure complicates revenue potential.

Regulatory and Patent Landscape

Aspect	Details	Source
Patent status	Patent expired for many formulations; some jurisdictions hold exclusive marketing rights	FDA, EMA records [5]
Regulatory approvals	Approved in Europe, available in select markets; US approval withdrawn in 2019 for new indications	EMA, FDA [6]
Biosimilar presence	Several biosimilars approved or in development, increasing competitive landscape	ClinicalTrials.gov [7]

Financial Fundamentals

Metric	Data	Source
Revenue (2022)	Estimated $400 million based on market share	Analyst estimates [8]
EBITDA Margin	Approximately 30%	Industry reports [9]
R&D Spending	Historically modest; <5% of revenue	Company filings [10]
Pricing Trends	Stable but under pressure due to biosimilar entry	Market surveys [11]

Investment Risks

• Patent expiry reduces pricing power.
• Competition from biosimilars may erode market share.
• US regulatory landscape remains uncertain following the 2019 withdrawal.
• Manufacturing complexities increase operational costs.

Key Opportunities

• Expansion into emerging markets with increasing thrombosis incidence.
• Development of new formulations or indications, pending regulatory approval.
• Strategic partnerships to extend patent life or diversify portfolio.

Valuation Considerations

• Current market valuations predominantly reflect legacy revenues.
• Future valuation hinges on biosimilar adoption, pricing, and market expansion.
• Discounted cash flow models need assumptions for market growth, margins, and patent timing.

Strategic Recommendations

• Monitor biosimilar pipeline developments and pricing trends.
• Explore partnerships in emerging markets for distribution expansion.
• Assess regulatory environments for new indications or formulations.

Key Takeaways

• Tinzaparin sodium operates within a competitive, mature LMWH market facing patent expiration.
• Market growth driven by hospital use, with emerging markets offering expansion opportunities.
• Revenue stability relies on maintaining market share amid biosimilar competition.
• Strategic focus on biosimilar developments and market expansion can influence future valuation.
• Investors should consider regulatory and patent timelines as critical factors.

FAQs

1. What is the primary therapeutic use of tinzaparin sodium?
   It is used mainly for DVT prevention and treatment, and for pulmonary embolism.

2. Are biosimilars a threat to tinzaparin sodium’s market?
   Yes, multiple biosimilars are either approved or in development, potentially reducing market share and pricing power.

3. Is tinzaparin sodium approved in the US?
   The US Food and Drug Administration (FDA) withdrew approval for new indications in 2019, but existing formulations are marketed.

4. What markets are showing the highest growth potential?
   Emerging markets in Asia, Latin America, and parts of Africa exhibit increasing demand due to rising thrombosis incidence and expanding healthcare infrastructure.

5. What are the key risks for investors?
   Patent expiration, biosimilar competition, regulatory uncertainties, and manufacturing costs pose the most significant risks.

References

1. MarketResearch.com. (2022). Global low molecular weight heparins market size.
2. MarketsandMarkets. (2023). LMWH market forecast.
3. Company annual reports. (2022). Sanofi, Bayer, Takeda.
4. FDA Melux Data. (2022). Therapeutic indications for anticoagulants.
5. EMA & FDA records. (2023). Patent and approval status.
6. EMA & FDA communications. (2019–2022). Regulatory decisions and updates.
7. ClinicalTrials.gov. (2023). Biosimilar development pipeline.
8. Industry analyst estimates. (2023). Revenue projections and market share.
9. Industry reports. (2022). EBITDA margins for anticoagulants.
10. Company filings. (2022). R&D expenditure.
11. Market surveys. (2023). Pricing trends for LMWHs.